REPORT FROM THE 63rd ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY (AAN), HONOLULU, HAWAII, APRIL 9-16, 2011- Three new studies presented at the AAN annual meeting have failed to provide supportive evidence of chronic cerebrospinal venous insufficiency (CCSVI) in MS.
Latest News
Depression correlated with Lewy bodies, neuronal loss
March 30, 2011An autopsy study of brains of non-dementia subjects with reported depression during their lifetime suggests that there are discrete neuropathological correlates of late-life depression (Tsopelas et al. Br J Psychiatry 2011; 198: 109-114).
Need to re-examine treatment-resistant schizophrenia, clozapine use
March 30, 2011The positioning of the atypical antipsychotic clozapine as a third-line treatment warrants re-examination since this has led to its underutilization in patients with treatment-refractory schizophrenia, according to a new Canadian review (Agid et al. Can J Psychiatry 2010; 55: 677-684).
B cell drug set to enter phase III testing
March 30, 2011Ocrelizumab, a novel anti-CD20 monoclonal antibody, is set to enter phase III testing in MS, according to industry newsletter FierceBiotech (www.fiercebiotech.com). The announcement was made at an investor event hosted by Roche. The drug was developed by Genentech, a subsidiary of Roche, and Biogen Idec.